O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide

Cancer

Volumn 118, Issue 18, 2012, Pages 4545-4554

  Lechapt Zalcman, Emmanuèle ^a,b,c,d   Levallet, Guénaëlle ^a   Dugué, Audrey Emmanuelle ^a   Vital, Anne ^e   Diebold, Marie Danièle ^f   Menei, Philippe ^g   Colin, Philippe ^h   Peruzzy, Philippe ^f   Emery, Evelyne ^a   Bernaudin, Myriam ^b,c,d   Chapon, Françoise ^a   Guillamo, Jean Sébastien ^a,b,c,d  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE CAEN   (France)

^d DIF   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h Polyclinic Courlancy   (France)

Author keywords

carmustine wafer; glioblastoma; immunohistochemistry; methylation; methylation specific polymerase chain reaction; O6 methylguanine DNA methyltransferase

Indexed keywords

CARMUSTINE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFICACY; ETHNIC GROUP; FEMALE; FRENCH LANGUAGE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN METHYLATION; RADIODENSITOMETRY; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84865971148     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27441     Document Type: Article

References (21)

1. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG,. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59: 793-797.
2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
3. Brell M, Tortosa A, Verger E, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005; 11: 5167-5174.
4. Everhard S, Tost J, El Abdalaoui H, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009; 11: 348-356.
5. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27: 5881-5886.
6. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ,. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest. 2007; 87: 392-397.
7. Brell M, Ibanez J, Tortosa A,. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction [serial online]. BMC Cancer. 2011; 11: 35.
8. Sciuscio D, Diserens AC, van Dommelen K, et al. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res. 2011; 17: 255-266.
9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
10. Metellus P, Coulibaly B, Nanni I, et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer. 2009; 115: 4783-4794.
11. Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009; 11: 281-291.
12. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol. 2010; 17: 1740-1746.
13. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J,. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol. 2008; 115: 249-259.
14. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
15. Karayan-Tapon L, Quillien V, Guilhot J, et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by 5 different methods. J Neurooncol. 2010; 97: 311-322.
16. Noel G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas [published online ahead of print February 5, 2011]. Int J Radiat Oncol Biol Phys. 2011.
17. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009; 110: 583-588.
18. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466.
19. Shah N, Lin B, Sibenaller Z, et al. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM [serial online]. PLoS One. 2011; 6: e16146.
20. Preusser M, Charles Janzer R, Felsberg J, et al. Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008; 18: 520-532.
21. Shamsara J, Sharif S, Afsharnezhad S, et al. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma. Cancer Invest. 2009; 27: 825-829.